Research programme: GPR119 protein agonists - Metabolex

Drug Profile

Research programme: GPR119 protein agonists - Metabolex

Latest Information Update: 20 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 10 Dec 2013 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (PO)
  • 28 Apr 2011 GPR119 protein agonists are no longer licensed to sanofi-aventis worldwide
  • 28 Jun 2010 Metabolex and sanofi-aventis enter into a global licensing agreement for discovery, development, manufacture and commercialisation of small molecule GPR 119 agonists for the treatment of type 2 diabetes ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top